

# Product Name: RelB (phospho Ser552) Rabbit Polyclonal Antibody

Catalog #: APRab05362

For research use only.

## **Summary**

**Description** Rabbit polyclonal Antibody

**Host** Rabbit

**Application** WB,IHC,ICC/IF,ELISA

Reactivity Human, Mouse
Conjugation Unconjugated
Modification Phosphorylated

**Isotype** IgG

ClonalityPolyclonalFormLiquidConcentration1mg/ml

**Storage** Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.

**Shipping** Ice bags

Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type **Buffer** 

preservative N.

**Purification** Affinity purification

## **Application**

**Dilution Ratio** WB 1:500-1:2000,IHC 1:100-1:300,ICC/IF 1:50-1:200,ELISA 1:10000-1:20000

Molecular Weight 62kDa

# **Antigen Information**

Gene Name RELB

Alternative Names RELB; Transcription factor RelB; I-Rel

 Gene ID
 5971.0

 SwissProt ID
 Q01201

The antiserum was produced against synthesized peptide derived from human RelB around Immunogen

the phosphorylation site of Ser552. AA range:530-579

## **Background**

caution: Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838




B,,domain:Both N- and C-terminal domains are required for transcriptional activation, function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelBp50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49, induction: By mitogens., PTM: Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation., similarity: Contains 1 RHD (Rel-like) domain., subunit: Component of the NFkappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID., caution: Was originally (PubMed:1577270) thought to inhibit the transcriptional activity of nuclear factor NF-kappa-B., domain: Both N- and C-terminal domains are required for transcriptional activation, function: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NFkappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.,induction:By mitogens.,PTM:Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation, similarity: Contains 1 RHD (Rel-like) domain, subunit: Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID.,

#### **Research Area**




#### MAPK\_ERK\_Growth;MAPK\_G\_Protein;


### **Image Data**



Enzyme-Linked Immunosorbent Assay ( Phospho-ELISA ) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right) , using RelB (Phospho-Ser552) Antibody



Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using RelB (Phospho-Ser552) Antibody. The picture on the right is blocked with the phospho peptide.



Western blot analysis of lysates from LOVO cells and RAW264.7 cells, using RelB (Phospho-Ser552) Antibody. The lane on the right is blocked with the phospho peptide.